Home » Stocks » TRVN

Trevena, Inc. (TRVN)

Stock Price: $1.33 USD -0.07 (-5.00%)
Updated Jul 30, 2021 4:00 PM EDT - Market closed
After-hours: $1.35 +0.02 (1.50%) Jul 30, 7:53 PM
Market Cap 218.80M
Revenue (ttm) 3.28M
Net Income (ttm) -33.49M
Shares Out 160.51M
EPS (ttm) -0.23
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day July 30
Last Price $1.33
Previous Close $1.40
Change ($) -0.07
Change (%) -5.00%
Day's Open 1.38
Day's Range 1.33 - 1.40
Day's Volume 2,073,874
52-Week Range 1.33 - 3.68

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

TRV027 will be dosed in ~300 patients in nationwide trial led by Vanderbilt University Medical Center (VUMC) TRV027 will be dosed in ~300 patients in nationwide trial led by Vanderbilt University Medica...

4 days ago - GlobeNewsWire

Glass Lewis and Institutional Shareholder Services (ISS) independently recommend that Trevena shareholders vote “FOR” proposals to approve a Reverse Stock Split and concurrent Authorized Share Reduction...

1 week ago - GlobeNewsWire

Models demonstrate substantial overall cost savings for hospitals when using OLINVYK compared to IV morphine in postoperative care

2 weeks ago - GlobeNewsWire

Nhwa is conducting and funding this study to support NDA regulatory filing in China

3 weeks ago - GlobeNewsWire

-- Study is evaluating the role of age and weight in a comparative analysis of the effect of OLINVYK and morphine on respiratory function

3 weeks ago - GlobeNewsWire

Trevena (TRVN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

1 month ago - Zacks Investment Research

Trevena Inc (NASDAQ: TRVN) has announced that the National Institute on Drug Abuse (NIDA), part of the NIH, has resumed recruitment for its proof-of-concept study for TRV734. The Company has collaborate...

1 month ago - Benzinga

-- TRV734 reduced drug-seeking behavior in a preclinical model of relapse, suggesting its utility as a novel oral maintenance treatment for opioid use disorder

1 month ago - GlobeNewsWire

-- Models demonstrate substantial overall cost savings for hospitals when using OLINVYK compared to IV morphine in postoperative care

2 months ago - GlobeNewsWire

Trevena Inc's (NASDAQ: TRVN) TRV027 has been selected for an NIH ACTIV trial in COVID-19 patients that will be dosed in ~300 COVID-19 patients. TRV027 combats disruption within the renin-angiotensin-ald...

2 months ago - Benzinga

-- Vanderbilt University Medical Center (VUMC) is coordinating multiple-arm, multi-site ACTIV-4d study targeting RAAS

2 months ago - GlobeNewsWire

-- Company reaffirms YE target of 100 formulary approvals for OLINVYK®

2 months ago - GlobeNewsWire

Trevena Inc (NASDAQ: TRVN) has announced that its novel AT1 receptor-selective agonist, TRV027, has been selected for inclusion in an international Phase 2-Phase 3 trial in COVID-19 patients. The trial ...

3 months ago - Benzinga

-- REMAP-CAP is led by experts in pandemic response and builds upon a worldwide clinical trial network evaluating treatments for COVID-19

3 months ago - GlobeNewsWire

-- Models demonstrate substantial overall cost savings for hospitals when using OLINVYK compared to IV morphine in postoperative care

3 months ago - GlobeNewsWire

These high-risk, high-reward healthcare stocks have outperformed the market over the past year.

Other stocks mentioned: TNXP
3 months ago - The Motley Fool

Trevena (TRVN) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front

4 months ago - Zacks Investment Research

Searching for stocks with above-average growth potential? Look no further.

Other stocks mentioned: AGX, CWBHF
4 months ago - The Motley Fool

-- Company to host conference call on March 9th, 2021, at 8:00 a.m. ET

4 months ago - GlobeNewsWire

-- Low incidence of respiratory depression observed with OLINVYK (oliceridine) injection regardless of age or body mass index, in exploratory analysis

6 months ago - GlobeNewsWire

Trevena's Catalyst-Filled Q1

6 months ago - Seeking Alpha

CHESTERBROOK, Pa., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with centr...

6 months ago - GlobeNewsWire

-- P resentations highlight efficacy of TRV045 in animal models of neuropathic pain and epilepsy

7 months ago - GlobeNewsWire

-- OLINVYK s ignificantly reduced risk of vomiting and rescue antiemetic use compared to IV morphine in a retrospective analysis

8 months ago - GlobeNewsWire

OLINVYK is headed for commercial availability, likely by Q1 '21, even though distribution can occur as early as late November following DEA scheduling. Trevena still has a busy 2021 full of catalysts.

8 months ago - Seeking Alpha

-- Guggenheim Healthcare Talks - 2nd Annual Neuro/Immunology Day Conference November 16 th Stifel Virtual Healthcare Conference November 1 8 th

8 months ago - GlobeNewsWire

-- OLINVYK commercial supply on track and available in November

9 months ago - GlobeNewsWire

Trevena (TRVN) will provide updates on its newly launched drug and other pipeline products when it releases its third-quarter 2020 results.

9 months ago - Zacks Investment Research

Is (TRVN) Outperforming Other Medical Stocks This Year?

9 months ago - Zacks Investment Research

-- Posters highlight improvements in respiratory safety and gastrointestinal tolerability associated with OLINVYK (oliceridine) injection vs. IV morphine

9 months ago - GlobeNewsWire

As of late, it has definitely been a great time to be an investor in Trevena.

10 months ago - Zacks Investment Research

-- Live presentation highlighting TRV027 as a potential treatment for COVID-19 acute respiratory distress syndrome (ARDS) / abnormal clotting

10 months ago - GlobeNewsWire

Investors need to pay close attention to Trevena (TRVN) stock based on the movements in the options market lately.

10 months ago - Zacks Investment Research

An analyst initiates coverage on the stock with an unequivocal buy recommendation.

10 months ago - The Motley Fool

- H.C. Wainwright: 22nd Annual Global Investment Conference - September 14th

10 months ago - GlobeNewsWire

Trevena: Strong Buy After Opioid Approval And Potential Supplementary COVID-19 Value

10 months ago - Seeking Alpha

Trevena (NASDAQ: TRVN) shares are trading higher on Friday after Cantor Fitzgerald initiated coverage on the company's stock with an Overweight rating and announced a $5 price target.

11 months ago - Benzinga

-- Publication in Anesthesiology: Favorable benefit-risk profile for OLINVYK (oliceridine) injection as measured by clinical utility function analysis

11 months ago - GlobeNewsWire

Trevena (NASDAQ: TRVN) shares traded higher on Monday after the company announced the initiation of its TRV027 study in COVID-19 patients in collaboration with Imperial College London.

11 months ago - Benzinga

-- TRV027 is a novel AT1 receptor selective agonist with the potential to treat acute lung damage / abnormal blood clotting associated with COVID-19

11 months ago - GlobeNewsWire

-- $3 million milestone payment for U.S. approval of OLINVYK™ (oliceridine) injection

11 months ago - GlobeNewsWire

Investors need to pay close attention to Trevena (TRVN) stock based on the movements in the options market lately.

11 months ago - Zacks Investment Research

CHESTERBROOK, Pa., Aug. 14, 2020 (GLOBE NEWSWIRE) -- Trevena, Inc. (TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central ner...

11 months ago - GlobeNewsWire

The biopharmaceutical company announced the pricing of a public offering of common stock.

11 months ago - The Motley Fool

CHESTERBROOK, Pa., Aug. 12, 2020 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN) (“Trevena” or the “Company”), a biopharmaceutical company focused on the development and commercialization of novel me...

11 months ago - GlobeNewsWire

CHESTERBROOK, Pa., Aug. 11, 2020 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with cen...

11 months ago - GlobeNewsWire

The biotech's innovative painkiller is the first new drug in its class in decades.

11 months ago - The Motley Fool

OLINVYK is a new chemical entity approved in adults for the management of acute pain severe enough to require an IV opioid analgesic

11 months ago - GlobeNewsWire

Trevena (TRVN) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.

1 year ago - Zacks Investment Research

Oliceridine is a new chemical entity intended for the management of moderate-to-severe acute pain Oliceridine is a new chemical entity intended for the management of moderate-to-severe acute pain

1 year ago - GlobeNewsWire

About TRVN

Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV027 for the treatment of acute lung injury contributing to acute respiratory distress syndrome and abnormal blood clotting in patients with COVID-19; TRV250, a G protein biased delta-opioid receptor agon... [Read more...]

Industry
Biotechnology
IPO Date
Jan 31, 2014
CEO
Carrie Bourdow
Employees
25
Stock Exchange
NASDAQ
Ticker Symbol
TRVN
Full Company Profile

Financial Performance

In 2020, Trevena's revenue was $3.07 million, an increase of 9,800.00% compared to the previous year's $31,000. Losses were -$29.37 million, 18.1% more than in 2019.

Financial Statements

Analyst Forecasts

According to 4 analysts, the average rating for Trevena stock is "Buy." The 12-month stock price forecast is 5.33, which is an increase of 300.75% from the latest price.

Price Target
$5.33
(300.75% upside)
Analyst Consensus: Buy